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Abstract.  
The potential use of human Decidua-derived mesenchymal stem cells (DMSCs) 
as a platform to carry mesoporous silica nanoparticles in cancer therapy has 
been investigated. Two types of nanoparticles were evaluated. The 
nanoparticles showed negligible toxicity to the cells, a fast uptake and a long 
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retention inside them. Nanoparticle location in the cell was studied by 
colocalization with the lysosomes. Moreover, the in vitro and in vivo migration of 
DMSCs towards tumors was not modified by the evaluated nanoparticles. 
Finally, DMSCs transporting doxorubicin-loaded nanoparticles were capable of 
inducing cancer cell death in vitro. 
1. Introduction 
The use of nanotechnology for drug delivery is nowadays changing the fields of 
biotechnology and biomedicine, allowing the incorporation of multiple 
therapeutic, sensing and targeting agents into nanoparticles (NPs).[1,2] Those 
NPs can be manufactured with a great variety of compositions and/or 
structures.[3] Among the different types of NPs, mesoporous silica NPs offer 
superior structural properties compared to other NPs, such as, large surface 
area and pore volume, tunable pore sizes, colloidal stability and robustness that 
allows straightforward functionalization of the silica walls.[4–6] NPs have been 
widely investigated as carriers for targeted drug delivery to cancer cells 
because they can overcome several inconveniences of systemic drug 
administration, such as poor solubility and limited stability of several drugs and 
side-effects due to non-specific uptake of the cytotoxic drugs by healthy 
cells.[7–9] In this sense, a key aspect of this technology is that NPs can be 
targeted and delivered into the tumors, which can be achieved by either passive 
targeting, through the enhanced permeability and retention (EPR) effect,[10,11] 
or active targeting, through the functionalization of nanoparticle surface with 
certain affinity ligands that would be specifically recognized by the targeted 
diseased cells.[12] However, the recent progress in nanotechnology has not 
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achieved the expected results in improving drug targeting,[13,14] highlighting 
the need of a better localization of the nanoparticles towards the tumor sites. 
Human mesenchymal stem cells (MSCs), which are multipontent progenitors 
cells that maintain and regenerate connective tissues,[15] present migratory 
properties towards tumors. Those inherent tumor tropism and migratory 
properties suggest their possible use as carriers of NPs to isolated tumors and 
metastasic diseases.[16,17] A particular type of MSCs, those from the decidua 
of human placenta, have shown migratory capacity towards tumors in vitro, as 
well as in a preclinical model of breast tumors.[18] Although the driving force for 
DMSCs to migrate into tumor sites is unknown, it is already well known that 
human MSCs have high tropism towards tumors.[19] The inflammatory tumor 
microenvironment enables human MSCs to specifically home to tumor tissues. 
Several factors such as cytokines, growth factors, receptors, extracellular matrix 
and inflammation factors appear to be involved in this migration capacity.[20,21]  
More interestingly, DMSCs have been observed to inhibit the growth of primary 
tumors and the development of new tumors[18]. These observations, together 
with the facts that DMSCs are easy to obtain and constitute a homogeneous 
population, inspired the idea of using them as therapeutic agents and as cellular 
vehicles of nanoparticles towards tumors. 
The aim of the present work is to exploit the benefits of the chemistry and 
biology of both systems. On one hand, NPs can be loaded with different 
chemical molecules and their surface can be easily modified with diverse 
chemical groups. On the other hand, the biological abilities of DMSCs, including 
the migration features towards tumors and the inherent inhibition of the growth 
of certain tumors, motivated the use of those cells as carriers of NPs towards 
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tumor cells. Although the idea of introducing NPs in MSCs has been already 
reported for actively targeted delivery,[22] this article investigates for the first 
time whether human DMSCs could be employed as a platform to load NPs and 
carry them to tumors for future anticancer therapies.  
DMSCs, like other MSCs, are adult stem cells without the ethical concerns of 
embryonic cells, they present a low risk of viral infection and have low or non-
immune response, and also show genomic stability under extended culture 
periods. Further, DMSCs present additional advantages respect to other MSCs 
sources, such us, the cells are easy to obtain, in a greater number and without 
invasive procedures. Moreover, the capacities of proliferation and differentiation 
of MSCs from other sources such as bone marrow or adipose tissue, are 
variable and dependent of the donor age while DMSCs present a high 
proliferantion and differentiation capacity. All these characteristics of DMSCs 
suggest that they could be considered a good and safe product for future 
clinical applications. 
This work explores the internalization of two different types of NPs into 
DMSCs, the cellular retention capacity of the NPs, their effect on DMSCs 
survival and, the in vitro and in vivo migration capacity towards mammary tumor 
tissue. Also, the capacity of DMSCs carrying drug-loaded NPs to induce cancer 
cell death was evaluated. The integration of NPs with DMSCs would allow the 
design of a multifunctional platform for effective treatment of diseases such as 
cancer. 
2. Experimental Section. 
2.1 Fabrication and characterization of dye-doped NPs. 
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NPs were synthesized by modifying previous methods.[23] Briefly, APTES-dyes 
were synthesized by labeling 3-aminopropyl triethoxysilane (APTES) with active 
groups of dyes. For example, APTES (2.2 µL) was labeled with 1 mg of 
fluorescein isothiocyanate (FITC) in 100 µL of ethanol solution. The reaction 
mixture was stirred at room temperature for 2 h. Separately, cetyl- 
trimethylammonium bromide (CTAB) (1 g) was dissolved in 480 mL of deionized 
water and 3.5 mL of 2M NaOH were added with magnetic stirring. The mixture 
was heated to 80 ºC and left for 30 min. Then, 5 mL of tetraethyl orthosilicate 
(TEOS) for negatively-charged NPs (neg-NPs), or a mixture of TEOS and 
APTES (4.5 and 0.5 mL, respectively), for positively-charged NPs (pos-NPs), 
was added slowly during 20 min, then the particles were left at 80 ºC under 
stirring for 2 h. The resulting particles were collected by centrifugation and then 
washed three times with deionized water and ethanol, respectively. The 
surfactant template was removed by ion exchange using an extracting solution 
of NH4NO3 (10 mg/mL) in EtOH (95 %). The particles were suspended in that 
medium and magnetically stirred at 75 ºC overnight. The particles were 
centrifuged and washed three times with deionized water and ethanol. 
Surfactant removal was confirmed by thermogravimetric analysis. 
All the reagents used for the synthesis of NPs were commercial products 
(Sigma-Aldrich, Spain) and were used without further purification. 
The materials were analyzed by X-ray diffraction (XRD) in a Philips X-Pert 
MPD diffractometer equipped with Cu Kα radiation. Thermogravimetry and 
Differential Temperature Analysis (TGA/DTA) were performed in a Perkin Elmer 
Pyris Diamond TG/DTA analyser, with 5oC/min heating ramps, from room 
temperature to 600ºC. Fourier Transformed Infrared (FTIR) spectra were 
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obtained in a Nicolet (Thermo Fisher Scientific) Nexus spectrometer equipped 
with a Smart Golden Gate Attenuated Total Reflectance (ATR) accessory. 
Surface morphology was analysed by Scanning Electron Microscopy (SEM) in a 
JEOL 6400 Electron microscope. Transmission Electron Microscopy (TEM) was 
carried out with a JEOL JEM 2100 instrument operated at 200 kV, equipped 
with a CCD camera (KeenView Camera). N2 adsorption was carried out on a 
Micromeritics ASAP 2010 instrument; surface area was obtained by applying 
the Brunauer, Emmet &Teller (BET) method to the isotherm and the pore size 
distribution was determined by the Barrett, Joyner & Halenda (BJH) method 
from the desorption branch of the isotherm. The mesopore size was determined 
from the maximum of the pore size distribution curve. The Z-potential and 
hydrodynamic size of nanoparticles were measured in deionized water by 
means of a Zetasizer Nano ZS (Malvern Instruments) equipped with a 633 nm 
“red” laser.  
2.2 Isolation and culture of DMSCs. 
Human placentas from healthy mothers were obtained from the Department of 
Obstetrics and Gynecology under written informed consent approved by the 
Ethics Committee from Hospital Universitario 12 de Octubre. Processing of 
placental membranes and culture of primary cells was done as previously 
described.[18,24] Briefly, extra- embryonic membranes (amnion, chorion [fetal 
origin] and decidua [maternal origin]) were processed by enzymatic digestion 
with trypsin-EDTA (Lonza, Spain). Isolated cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 2 mM of glutamine, 0.1 
mM of sodium pyruvate, 55mM β-mercaptoethanol, 1 % non-essential amino 
acids, 1 % penicillin/streptomycin, 10 % fetal bovine serum and 10 ng/mL of 
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EGF (epidermal growth factor), at 37 ºC, 5 % CO2 and 95 % humidity. Non-
adherent cells were discarded after 5 days. In our preceding study, we reported 
the morphology, phenotype, maternal origin and MSCs characteristics of 
DMSCs.[24] At confluence, adherent cells were passaged and seeded at a 
density of 104 cells per cm2.  
2.3 Cellular uptake of particles by DMSCs.  
DMSCs were plated 24 h before the start of the experiment in culture multiwell 
plates at a density of 104 cells per cm2. After incubation with 200 µg/mL 
particles for 2 h, the media were replaced by fresh media and cells were 
incubated for one additional hour. The cells were fixed with Z-fix solution 
(Anatech, USA) for 15 min, permeabilized with 0.1 % Triton X-100 in phosphate 
buffer saline (PBS) solution, at room temperature, for 5 min and, subsequently 
incubated for 20 min with Alexa Fluor®568 phalloidin (Invitrogen, Spain) for 
staining F-actin. DAPI (40,60 diamidino-2-phenylindole) at 1 μg/mL was used to 
stain and visualize the nuclei. Fluorescence microscopy was performed with an 
Evos® FL Cell Imaging System equipped with tree Led Lights Cubes (lEX (nm); 
lEM (nm)): DAPI (357/44; 447/60), GFP (470/22; 525/50), RFP (531/40; 593/40) 
from AMG (Advance Microscopy Group). Quantitative analysis of cellular uptake 
was performed by flow cytometry (FACS). 200 µg/mL particles were incubated 
with the DMSCs for the indicated time points, and then removed by washing 
three times and cells were incubated for one additional hour. Subsequently, the 
cells were trypsinised, collected by centrifugation and redispersed in PBS 
solution with trypan blue (0.5 %) to remove extracellular fluorescence. The 
fluorescence intensity of 10,000 cells was quantified by FACS. Statistical 
analysis for differences between groups was carried out by the Student´s t test. 
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Quantitative analysis of retention ability of particles was performed by FACS. 
Particles at a concentration of 200 µg/mL were incubated with the MSCs for 2 h, 
and then removed by washing three times. The cells were then cultured in fresh 
medium for indicated time points. Subsequently, the cells were collected by 
trypsinization and centrifugation, and redispersed in PBS solution with trypan 
blue (0.5 %). The fluorescence intensity of 10,000 cells was quantified by 
FACS. The fluorescence intensities obtained after the first day were corrected 
by the cell dilution folds due to cell division. 
2.4 Intracellular fate of NPs. 
For the co-localization of NPs and lysosomes, the cells were incubated with 200 
g/mL particles for 2 h. The cells were washed twice with PBS solution. Then, 
lysosomes were stained with the Cell Tracker® Lysosome staining kit following 
the manufacturer protocol (AAT Bioquest, Inc, USA). The cells were washed 
twice with PBS, and then fresh medium was added. The cells were fixed and 
stained with DAPI as previously described. Fluorescence microscopy was 
performed with an Evos® FL Cell Imaging System. 
2.5 Cytotoxicity of NPs.  
The cytotoxicity of NPs was evaluated using the following standard protocols:  
Lactate dehydrogenase (LDH) activity test: Extracellular LDH activity was 
measured in the media using the kit for Quantitative determination of LDH 
(Spinreact, Spain). DMSCs were incubated with NPs for 24 h at different 
concentrations. Then, the culture medium was collected for measuring the 
extracellular LDH activity. The LDH activity was directly measured by 
spectrophotometer at 340 nm in the culture medium following the manufacturer 
protocol. 
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MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium) assay: The MTS reduction assay was performed 
using a commercial assay and following the manufacturer´s protocol (CellTiter® 
Aqueous One Solution Cell Proliferation Assay). Briefly, DMSCs were incubated 
with various concentrations of NPs for 2 h (n=3). The medium was replaced with 
600 µL culture medium including MTS, and the incubation proceeded for 3 h. 
The medium was then removed, and its absorption at 490 nm was measured 
using a microplate reader. 
2.6 Tissue homogenates from NMU-induced mammary tumors. 
N-nitroso-N-methylurea (NMU) tumors were induced in 45-day-old Sprague-
Dawley female rats according to our previously published protocol.[25] 
Concisely, NMU (Sigma-Aldrich, Spain) was administered once a week during 
two weeks by intra-peritoneal injection at a concentration of 5 mg/100g rat body 
weight. As well, metoclopramide (0.125 mg/L) was administered in the drinking 
water. Animals were palpated weekly for the detection of mammary tumors. 
The tumors were disected out from the animals, immediately frozen in liquid 
nitrogen and subsequently stored at -80 ºC until use.  
Homogenates were performed at 4 ºC as we previously described.[18] The 
protein concentration was measured using the Lowry protein assay kit (Biorad, 
Spain) following the manufacturer´s instructions. 
2.7 Transwell assay. 
The in vitro effect of mammary tumor homogenate on DMSCs migration 
capacity was determined using Millicell culture plate inserts with 8 μm pore 
polycarbonate membranes (Merk Millipore, Spain) in 24-well plates. Briefly, 
1.5x105 DMSCs in 300 µL of serum-free DMEM were seeded in the insert. 
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Tumor homogenate (5 mg/mL of protein concentration was added in the well 
below. Migration medium (serum-free DMEM) without tissue was used as a 
negative control. Migration was assessed at 24 h by the CytoSelect 24-Well Cell 
Migration Assay (8 μm, Colorimetric, Cell Biolabs, Bionova Cientifica, S.L., 
Spain). Non-migratory cells were removed from the top of the membrane and 
migratory cells on the bottom of the polycarbonate membrane were stained with 
the Cell Stain Solution and quantified according to manufacturer´s instructions. 
Migratory cells were visualized (three individual fields per insert) using a light 
microscope under x40 magnification objective. Color of stained cells was 
subsequently extracted with the Extraction Solution, and quantified by 
absorbance at 560 nm using the multimodal plate reader Enspire (Perkin 
Elmer). All experiments were done as a minimum in triplicate. 
2.8 In vivo migration. 
To evaluate the in vivo migration capacity of NP loaded DMSCs, cells were 
incubated with pos-NPs as previously described. After washing non-internalized 
NPs, 106 cells were injected into the circulation through the tail-vein of Spraw-
Dawley rats with NMU-mammary tumors. Seventy-two hours later, rats were 
anesthetized, and mammary tumors were removed and stored at -80ºC until 
use. Frozen tissue was sectioned in the cryostat, treated with Sudan Black to 
removed self-fluorescence following the manufacturer´s instructions, the nuclei 
were stained with DAPI for 1 min and sections were mounted with Vectashield 
and the tissue sections were visualized by fluorescence microscopy. 
2.9 In vitro experiments with doxorubicin-loaded NPs 
Doxorubicin was loaded in neg- and pos-NPs by stirring 10 mg of NPs in 5 mL 
of a 1 mg/mL solution of doxorubicin in PBS for 24 h. Doxorubicin-loaded NPs 
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(DOX-NPs) were washed by centrifugation and redispersion in PBS several 
times.  
DMSCs were incubated with 200 g/mL DOX-NPs for 2 h and washed 
with PBS to remove non-internalized nanoparticles. Cell viability was evaluated 
after 2 h, 1 day and 2 days by Alamar Blue assay, following the manufacturer´s 
instructions. Briefly, 10 % of the reagent was added to the culture medium with 
the DMSCs and incubated at 37 ºC for 1 h. Then, fluorescence at 560EX 
nm/590EM nm was measured in a microplate reader. Cell viability was then 
analyzed as a percentage of the control wells (DMSCs not exposed to DOX-
NPs). 
In order to determine the feasibility of using DOX-NPs inside DMSCs as 
a platform for future anticancer therapies, DMSCs with DOX-pos-NPs were co-
cultured with NMU rat mammary cancer cells (ATCC, LGC Standards S.L.U., 
Spain). NMU cells were cultured in 24 well plates at a density of 20,000 cells 
per well. Twenty four hours later, three wells were trypsinized and cells were 
counted. Then, DMSCs with DOX-pos-NPs (incubated as described previously) 
were seeded in Transwell® culture inserts (0.4 µm pore, polycarbonate 
membranes, tissue cultured treated, Costar®) in two different DMSCs:NMU 
ratios (1:2 and 1:5). After 4 days, the inserts were removed and NMU cells were 
trypsinized and stained with BD Pharmingen™ FITC Annexin V Apoptosis 
Detection Kit I, following the manufacturer´s instructions. Then, the cells were 
analyzed by FACS. Statistical analysis was peformed by the Student´s t test. 
 
3. Results and Discussion. 
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In order to evaluate DMSCs as potential carriers of NPs, mesoporous silica 
NPs (neg-NPs and pos-NPs) were synthesized according to a modified Stöber 
method [23]. Both types of NPs were covalently labeled with fluorescein by co-
condensation during nanoparticle synthesis in order to be able to follow the fate 
of the NPs in contact with cells by fluorescence microscopy. Regarding particle 
morphology, SEM micrographs showed NPs, neg-NPs and pos-NPs, with 
spherical shape. Additionally, well-ordered mesoporous channels could be 
appreciated in the corresponding TEM micrographs (Figure 1). In fact, typical 
XRD patterns of MCM-41 type materials were observed in all cases, with the 
three characteristic maxima (100), (110) and (200), confirming the 2D 
hexagonal order of the mesopores arrangement (Figure S1). N2 adsorption 
isotherms observed in all cases were type IV, with typical surface areas (1051 
and 1109 m2/g) and pore diameter (2.8 and 2.5 nm) for this type of negatively 
and positively-charged NPs, respectively. The NPs show a hydrodynamic 
particle diameter of ca. 190 nm. The charge of the NPs was confirmed through 
Z-potential (-31.5mV and +23.3mV, respectively), and the organic functionality 
through FTIR spectroscopy (Si-OH and –NH2 groups, respectively) (Figure S1). 
With respect to the interaction of the particles with the cells, in addition to 
size and shape, the NP surface is also a very important feature. The 
mechanism of NP internalization into the cell is generally via endocytosis,[26] a 
process in which extracellular materials are intracellularly incorporated into a 
membranous vesicle. The chemical groups attached to the surface of the NPs 
strongly influence their interaction with biological entities and, therefore, their 
internalization. In this sense, the surface of NPs can be easily modified through 
a functionalization process with a great variety of organic groups.[27] In an 
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effort to evaluate the contribution of surface chemistry, the effect of both charge 
and functionality on the cellular uptake, neg-NPs and pos-NPs was tested. 
First, we incubated NPs with DMSCs to evaluate the toxicity of the 
nanoparticles on these cells in culture. Both negatively and positively-charged 
NPs were dispersed in serum-free medium at different concentrations and 
incubated with DMSCs for 2 h. Then, the nanoparticles were withdrawn and the 
cells were cultured in complete medium for 24 h. Cell viability was examined by 
LDH release and MTS reduction assay (Figure 2). 
We observed that there was no increase in LDH released in the culture 
medium of DMSCs incubated with the NPs. This indicates that, at 24 h, the NPs 
did not induce cell death in DMSCs. Furthermore we looked to confirm these 
results using an assay that estimates the number of viable cells. The results of 
the MTS reduction assay (Figure 2) show that NPs did not induce significant 
toxicity over a very wide range of NP concentrations (at least up to 1 mg/mL). 
This is of great value for subsequent experiments because it is very important to 
have as much NPs as possible incorporated into cells. 
Once toxicity was found not to be an issue, the next step was to evaluate the 
endocytosis process, studying how long the NPs remain inside the cells 
(retention time) and describing their location within the cells, whether lysosomal 
or cytoplasmic. To evaluate the endocytosis process, both types of NPs 
(negatively and positively-charged) were dispersed in serum-free DMEM and 
incubated with DMSCs for different periods of time. The concentrations of NPs, 
100 and 200 µg/mL, were selected to avoid nanoparticle aggregates outside the 
cells (Figure S2). The NP suspension was then withdrawn and the cells were 
rinsed three times with PBS. Fluorescence microscopy images of DMSCs 
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incubated with neg-NPs and pos-NPs can be seen in Figure 3a. After staining 
cytoplasmatic actin with AlexaFluor®568 Phalloidin (red) and nuclei with DAPI 
(blue), NPs with a fluorescent dye attached are observed internalized into the 
cytoplasm of the DMSCs, with most cells carrying NPs when incubated at 200 
µg/mL. The morphology of the cells remained unmodified after NP 
internalization (Figure S3). 
When incubating NPs (green) with a concentration of 100 µg/mL, pos-NPs 
were observed to be internalized more efficiently than neg-NPs. The same trend 
was observed with higher concentrations (200 µg/mL). Thus, we found that 200 
µg/mL and 2 h were the optimal concentration and incubation time parameters 
for the best internalization results. Besides, pos-NPs were internalized better in 
DMSCs than neg-NPs, with many particles localized around the nucleus after 2 
h of incubation (Figure 3a).  
The uptake of NPs was quantified using flow cytometry at different times of 
internalization (Figure 3b). The cells were dispersed in trypan blue solution in 
order to remove extracellular fluorescence and quantify only internalized 
nanoparticles. The results showed that, at shorter periods of time, the amount of 
endocytosed NPs was higher for those negatively charged, probably due to an 
electrostatic interaction of the positively-charged particles with the cell surface, 
delaying their internalization. However, after two hours, both types of NPs were 
effectively endocytosed, with percentages of cells with internalized NPs close to 
85 % in all cases (Figure S4).  
Fluorescence intensity of internalized particles followed the same trend, with 
more neg-NPs internalized after 1 h than pos-NPs (Figure 3b). However, after 2 
h of incubation, the intensity of the pos-NPs was higher than the neg-NPs, 
15 
 
which indicates that the former NPs are better internalized than the later. All of 
these results are in agreement with previous results in the literature,[28] and 
could be explained by the stronger interaction of pos-NPs with negatively-
charged phospholipids in the cell membrane. In order to check that interaction, 
the same cells dispersed in PBS were analyzed by flow-cytometry and 
intracellular and membrane-adhered NPs were measured. The fluorescence of 
membrane-adhered NPs was estimated as the difference of cell fluorescence in 
PBS and cell fluorescence in trypan blue solution. This extracellular 
fluorescence was 2.5 times higher for pos-NPs than for neg-NPs (data not 
shown). In any case, the necessary time to complete the internalization process 
was found to be 2 h, so this was the incubation time of NPs with cells for the 
subsequent experiments. 
Once the NPs have been internalized, the next important parameter to 
consider is the retention time of the particles in the cells. According to previous 
studies by our group [18], it was found that 3 days is the necessary time for the 
DMSCs to reach the tumor tissues in an in vivo model, so the particles should 
remain in the cells a minimum of 3 days. The procedure to evaluate the 
retention capacity of the particles in DMSCs was similar to the uptake 
experiment, that is, cells were incubated with 200 µg/mL of both neg- and pos-
NPs for 2 h, then washed and cultured for up to 5 days. Figure 3c shows the 
normalized fluorescence intensity percentage of the cells at different culturing 
times, being almost constant for the neg-NPs, which means that those NPs 
were retained in the cytoplasm. Pos-NPs fluorescence was kept unchanged at 
the initial stages, but after 1 day the intensity increased up to ca. 140 %. This 
could be explained by a slow uptake of membrane-adhered nanoparticles due 
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to interactions between pos-NPs and negatively-charged phospholipids at the 
cell membrane.[28] This means that in terms of retention capacity, a greater 
amount of particles were observed in the group of pos-NPs than in the neg-
NPs. Most importantly, in all cases, NPs were still retained in the cells at day 5. 
Taking into account that it takes around 3 days for the cells to reach the tumor 
in the in vivo model previously evaluated,[18] those results guarantee that our 
NPs will be still in the cells when reaching the tumor tissue, validating our initial 
hypothesis of using DMSCs as carriers of nanoparticles. 
Once internalization and retention of NPs into living mesenchymal cells were 
validated, the next step was exploring the location of internalized NPs in the 
cells. NPs are normally transported to the endo-lysosomal system after 
internalization, and the ability of the NPs to escape from the lysosomes is an 
important parameter regarding the stability of the NPs.[17] 
A co-localization study was performed in DMSCs with internalized NPs by 
staining the cell lysosomes (Cell Navigator® Lysosome staining kit) and 
comparing the location within the cells of lysosomal red fluorescence and NP-
associated green fluorescence. We observed that NPs were located inside 
lysosomes just after internalization (Figure S5), independently of their surface 
charge. However, after 3 days, the location of NPs inside the cells was different 
for pos-NPs and neg-NPs (Figure 3d). In neg-NPs, the fluorescence due to NPs 
was co-localized within the lysosomes, which indicates that neg-NPs were not 
able to escape the lysosomes in that time. On the other hand, fluorescence 
from pos-NPs does not match the fluorescence of the cell lysosomes at day 3, 
which shows that these NPs had escaped the lysosomes, probably by a charge-
dependent mechanism previously described in the literature.[17] This result 
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indicates that pos-NPs could be a better option to be transported by DMSCs, as 
the lysosomal escape would ensure a less aggressive environment both for the 
NPs and its cargo.  
All the above results show the stability of NPs in DMSCs, which is a 
necessary requirement to combine both elements. The internalization of the 
NPs into the cells and their persistence has been shown so far, so we next 
evaluated the migration capacity of NP-loaded DMSCs towards tumors. The in 
vitro and in vivo migrating capability of DMSCs towards tumors has been 
previously observed by our research group.[18] Here we evaluated if DMSCs 
with uptaken NPs retained those tumor tropism properties in an in vitro 
migration study. Thus, their in vitro migration capability was analyzed in the 
presence and absence of tumor human breast homogeneate using a 
standardized transwell migration assay (Figure 4). DMSCs without particles 
(control) and with both types of NPs were tested.  
Compared to the migration in the absence of tumor homogenate, DMSCs migration 
capacity was almost 4 times higher when the tumor homogenate was present. 
Interestingly, the presence of any of the types of NPs (pos- and neg-) in the cells, did 
not appreciably affect the migration capacity of DMSCs toward tumor homogenate. 
Thus, combining these migration results together with cellular uptake, retention time 
and lysosomal leakage, it is clear that pos-NPs inside DMSCs is the best combination 
for the design of an efficient construct for drug delivery technologies. Therefore, pos-
NPs were chosen to study the in vivo migration of DMSCs towards mammary 
tumors. DMSCs were cultured with pos-NPs and injected into the tail vein of 
NMU-induced tumor rats. After 3 days, the tumors were surgically removed, and 
the presence of green-fluorescent NPs was examined by fluorescence 
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microscopy. The results presented in Figure 5 show the presence of NPs inside 
the tumors, located around of some nuclei in the tissue. This indicates that the 
DMSCs retain their in vivo homing capacity towards the tumors when carrying 
NPs. These results show the ability of the cells to transport the NPs to the 
diseased site. 
Regarding the antitumor application of this platform, NPs were loaded with 
doxorubicin, an anticancer drug. DOX-NPs were then incubated with DMSCs 
and cell viability was evaluated by Alamar Blue assay at different time points 
(Figure S6). DOX-neg-NPs induced significantly higher toxicity in DMSCs than 
DOX-pos-NPs after 2 days. This effect could be due to the higher doxorubicin 
loading capacity of neg-NPs previously reported in the literature,[29] which 
leads to higher toxicity. As a consequence, DOX-pos-NPs were chosen for the 
subsequent experiments. 
The therapeutic potential of this approach was evaluated through an in vitro 
co-culture assay, using DMSCs with DOX-pos-NPs and NMU mammary cancer 
cells. DMSCs with or without drug-loaded NPs were seeded in the Transwell 
culture insert and the insert placed on top of a well that contains the NMU cells. 
Two different DMSC:NMU ratios (1:2 and 1:5) were tested. After 4 days, the 
Transwell inserts were removed and the NMU cells were evaluated by FACS 
using an apoptosis/necrosis detection kit (BD Pharmingen™ FITC Annexin V 
Apoptosis Detection Kit I). The Figure 6 shows that a significant fraction of the 
cancer cells became apoptotic/necrotic (cells appear in the right quadrants of 
the dot plots FL1-H vs FL2-H) only when the DMSCs were carrying DOX-NPs. 
Furthermore, this effect also appears to be dose-dependent, observing lower 
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cancer cell viability when larger amounts of DMSCs transporting DOX-NPs 
were present. 
4. Conclusions. 
Mesoporous silica nanoparticles (NPs) show negligible toxicity after being 
incubated with human Decidua-derived mesenchymal stem cells (DMSCs). NP 
uptake by DMSCs is fast (2 h) and the particles are retained inside the cells for 
a long period of time (at least 5 days), more than enough for DMSCs to 
accumulate in the tumor environment. The presence of NPs inside DMSCs 
does not inhibit their tumor-tropic behavior in vitro and in vivo. DMSCs 
transporting doxorubicin-loaded NPs were capable of inducing cell death in 
NMU cancer cells when co-cultured in vitro. All of these results indicate that 
DMSCs could be a promising platform for cancer therapy as carriers of 
anticancer drug-loaded NPs. 
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Figure Captions. 
Figure 1. TEM (a, b) and SEM (c, d) micrographs of neg-NPs (left) and pos-
NPs (right). 
Figure 2. LDH release by DMSCs with internalized neg-NPs (blue)and pos-NPs 
(red) for 24 h(left); Cytotoxicity assay measured by MTS reduction of neg-NPs 
(blue)and pos-NPs (red) in DMSCs at 24 h after endocytosis (right). No 
significant differences were found at any of the evaluated concentrations (Data 
presented as Mean ± SD, N=3). 
Figure 3. Fluorescence images of NP-loaded DMSCs; blue (nucleus), red 
(cytoplasm), green (NPs) (a), Flow-cytometry data regarding neg-NPs (blue) 
and pos-NPs (red) uptake (b) and retention (c) (Mean ± SD, N=3, *p < 0.05) , 
Colocalization study of NPs (green), nucleus (blue) and lysosomes (red) in 
DMSCs after 3 days (d). 
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Figure 4. In vitro Transwell migration assay of DMSCs against culture medium 
(basal), tumor homogenate (control) and migration of NP-loaded DMSCs 
against tumor homogenate. (Mean ± SD, N=3, *p < 0.05) 
Figure 5. Fluorescence microscopy images of sections of NMU-induced rat 
adenocarcinomas after in vivo migration of DMSCs (images were taken 72 h 
after tail-vein injection of 106 DMSCs). Bright field images (a,c) of the tumor 
sections and Fluorescence images (b,d) of the same sections showing blue 
fluorescence of cell nuclei stained with DAPI and green fluorescence of the pos-
NPs, indicating the in vivo migration towards tumors of DMSCs carrying pos-
NPs.  
Figure 6. Flow cytometry results of NMU cells after co-culture in different ratios 
with DMSCs or with DMSCs with internalized doxorubicin-loaded pos-NPs 
(DMSCs-NPs). NMU population analyzed (a), Apoptosis/Necrosis evaluation of 
NMU cells showing viable cells (lower left quadrant), early apoptotic cells (lower 
right quadrant) and late apoptotic/necrotic cells (upper right quadrant) (b-f), 
Percentage of viable NMU cells after co-culture (g). (Mean ± SD, N=3, *p < 
0.05, **p < 0.01).  
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